...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Message: Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019

"Thanks BDZ,... that symposium sounds super interesting,... is that a sign of confidence,... ? Any chance they will announce TLD here,... if we met Primary Endpoint,...?"

They have been regularly doing symposia at ESC and ERA-EDTA for the past few years. But this is the first one that falls into "the zone" of the expected top-line data timeline. Definitely possible that top-line data is announced during ESC based on current guidance.


New Message
Please login to post a reply